Presentation is loading. Please wait.

Presentation is loading. Please wait.

Development and Health Economic Evaluation of a Novel Ambulatory Haematological Cancer Service. Dr Christopher Dalley Department of Haematology Sheffield.

Similar presentations


Presentation on theme: "Development and Health Economic Evaluation of a Novel Ambulatory Haematological Cancer Service. Dr Christopher Dalley Department of Haematology Sheffield."— Presentation transcript:

1 Development and Health Economic Evaluation of a Novel Ambulatory Haematological Cancer Service. Dr Christopher Dalley Department of Haematology Sheffield Teaching Hospitals NHS Foundation Trust

2 Overview Background Developing ambulatory care Outcomes Future plans

3

4 The Royal Hallamshire; Clinical Haematology Bone marrow transplant programme Largest treatment centre for blood cancer in S.Yorkshire Two inpatient wards and large day care ward

5 The problem; blood cancer care Intensive chemotherapy Side effects Lengthy inpatient stay Increasing demand Treatment closer to home

6 The solution Ambulatory care – Deliver key parts of patient care in day case or home environment – Reduce or avoid inpatient stays where possible – Deliver care safely

7 What we aimed to do Introduce new ambulatory care treatments – Patients with acute leukaemia (AML) – Patients with lymphoma needing high-dose therapy Clinical microsystems Evaluate – Economic impact – Patient experience

8 Implementing ambulatory pathways Clinical microsystems Microsystems team – Patients, nurses, doctors, pharmacist, hotel services, managers, health economist Training Weekly meetings Tools – PDSA, questionnaires, news clips, – Process mapping

9 Process mapping Admit ChemoSupportHome 28 days Patient stays in flat/home Ambulatory pathway AdmitChemoSupportHome Patient stays in ward Normal inpatient pathway 28 days

10 Supporting the ambulatory pathways New protocols and guidelines Patient & carer education programme Patient information booklets Patient alert card Ambulatory flats and hotel services Longer day ward opening hours including weekends

11

12 Outcomes Ambulatory patients with AML PatientAgeDays ambulatory Days inpatient Reason for readmission Nausea and vomiting Not applicable Infection Not applicable Not applicable

13 Ambulatory Care Patients

14 Outcomes Ambulatory patients with lymphoma PatientAgeDays ambulatory Days inpatient Reason for readmission Sore mouth Infection Sore mouth Sore mouth

15 Ambulatory Care Patients

16 Outcomes Health-economic School of Health and Related Research (ScHARR) Computer simulation used to assess impact of introducing new ambulatory care pathways alongside standard care pathways in a clinical unit. Various simulations used to measure effect of different degrees of ambulatory care Unit costs for ambulatory and standard pathways provided by RHH management team

17 Effect of ambulatory care provision on bed days and care costs 1 flat2 flats1 flat & home care 2 flats & home care Reduction in bed days per year Reduction in costs £54,210£65,185£81,823£74,409 Percentage reduction in costs 7.1%8.6%10.8%9.8%

18 Outcomes Patient experience

19 Establishing ambulatory care Department to write full business case to support ambulatory care: – Second ambulatory flat refurbished – Ambulatory co-ordinator post to be appointed Presenting our findings: – Local (Cancer Board Haemato-oncology group) – Nationally (Shelford group) – International-(EBMT Geneva, April 2012)


Download ppt "Development and Health Economic Evaluation of a Novel Ambulatory Haematological Cancer Service. Dr Christopher Dalley Department of Haematology Sheffield."

Similar presentations


Ads by Google